Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy.

摘要: Antiretroviral therapy (ART) effectively slows the progression of AIDS. However, drug resistance and/or toxicity can limit utility ART in many patients. In this study, we assessed whether a viral vector-based vaccine be used as therapeutic simian immunodeficiency virus (SIV)-infected monkeys. The effect vaccinating SIVmac239-infected rhesus monkeys with an SIV gag and gp120-expressing adenovirus (Ad) vector modified vaccinia Ankara (MVA) was explored while being treated ART. Rhesus were intravenously infected 10 1000 TCID(50) (50% tissue culture infectious dose) SIVmac239. Two months after infection, received 4-month treatment Some immunized adenovirus-based MVA-based 2 interval during Viral load, CD4 count SIV-specific immune responses observed for 7 interruption vaccinated animals had higher (i) counts, (ii) cell-mediated (iii) anti-SIV-neutralizing antibody (Ab) titers than alone. More importantly, vaccination significantly reduced RNA load from low dose (10 TCID(50)). anti-SIV humoral induced by inversely correlated reduction positively increase CD4(+) T cell counts. These results suggest that improve antiviral immunity, which may contribute to controlling replication.